ME02461B - Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih - Google Patents

Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih

Info

Publication number
ME02461B
ME02461B MEP-2016-96A MEP9616A ME02461B ME 02461 B ME02461 B ME 02461B ME P9616 A MEP9616 A ME P9616A ME 02461 B ME02461 B ME 02461B
Authority
ME
Montenegro
Prior art keywords
amino
methyl
fluorophenyl
oxadiazol
bromo
Prior art date
Application number
MEP-2016-96A
Other languages
English (en)
Inventor
Andrew P Combs
Eddy W Yue
Original Assignee
Incyte Holdings Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37396891&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02461(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Incyte Holdings Corp filed Critical Incyte Holdings Corp
Publication of ME02461B publication Critical patent/ME02461B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Claims (14)

1. Jedinjenje formuleili njegova farmaceutski prihvatljiva so, za upotrebu u tretmanu kancera u kombinaciji sa anti-PD-1 antitelom gde su: W, X1, i X2 nezavisno izabrani od (CRaRb)t, (CRaRb)uO(CRaRb)v, (CRaRb)uC(O)(CRaRb)v, (CRaRb)uC(O)NRc(CRaRb)v, (CRaRb)uC(O)O(CRaRb)v, (CRaRb)uC(S)(CRaRb)u, (CRaRb)uC(S)NRc(CRaRb)v, (CRaRb)uS(O)(CRaRb)v, (CRaRb)uS(O)NRc(CRaRb)v, (CRaRb)uS(O)2(CRaRb)v, (CRaRb)uS(O)2NRc(CRaRb)v, (CRaRb)uNRc(CRaRb)v i (CRaRb)uC(=NRd)NRc(CRaRb)v;R2 je H, C1-6 alkil ili C3-7 cikloalkil;R3a i R5a su nezavisno izabrani od C1-8 alkila, C2-8 alkenila, C2-8 alkinila, arila, cikloalkila, heteroarila i heterocikloalkila, svaki opciono supstituisan sa 1, 2, 3, 4 ili 5 supstituenata nezavisno izabranih od halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-4 haloalkila, Cy1, CN, NO2, ORe1, SRe1, C(O)Rf1, C(O)NRg1Rh1, C(O)ORe1, OC(O)Rf1, OC(O)NRg1Rh1, NRg1C(O)NRg1Rh1, NRg1Rh1, NRg1C(O)Rf1, NRg1C(O)ORe1, C(=NRi)NRg1Rh1, NRg1C(=NRi)NRg1Rh1, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORe1ORf1, S(O)Rf1, S(O)NRg1Rh1, S(O)2Rf1 i S(O)2NRg1Rh1;R3b je aril ili heteroaril svaki opciono supstituisan sa 1, 2, 3, 4 ili 5 supstituenata nezavisno izabranih od halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-4 haloalkila, C1-4 hidroksialkila, Cy2, CN, NO2, ORe1, SRe1, C(O)Rf1, C(O)NRg1Rh1, C(O)ORe1, OC(O)Rf1, OC(O)NRg1Rh1, NRg1C(O)NRg1Rh1, NRg1Rh1, NRg1C(O)Rf1, NRg1C(O)ORe1, C(=NRi)NRg1Rh1, NRg1C(=NRi)NRg1Rh1, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORe1ORf1, S(O)Rf1, S(O)NRg1Rh1, S(O)2Rf1 i S(O)2NRg1Rh1;R5b je H, C1-8 alkil, C2-8 alkenil, C2-8 alkinil, aril, cikloalkil, heteroaril ili heterocikloalkil gde su spomenuti C1-8 alkil, C2-8 alkenil, C2-5 alkinil, aril, cikloalkil, heteroaril ili heterocikloalkil opciono supstituisani sa 1, 2, 3, 4 ili 5 supstituenata nezavisno izabranih od halo, C1-6 alkila, C2-6 alkenilaC2-6 alkinila, C1-4 haloalkila, C1-4 hidroksialkila, Cy2, CN, NO2, ORe1, SRe1, C(O)Rf1, C(O)NRg1Rh1, C(O)ORe1, OC(O)Rf1, OC(O)NRg1Rh1, NRg1C(O)NRg1Rh1, NRg1Rh1, NRg1C(O)Rf1, NRg1C(O)ORe1, C(=NRi)NRg1Rh1, NRg1C(=NRi)NRh1R, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORe1ORf1, S(O)Rf1, S(O)NRg1Rh1, S(O)2Rf1 i S(O)2NRg1Rh1;Cy1 i Cy2 su opciono izabrani od arila, heteroarila, cikloalkila i heterocikloalkila, svaki supstituisan sa 1, 2, 3, 4 ili 5 supstituenata nezavisno izabranih od halo, C1-4 alkila, C2-4 alkenila, C2-4 alkinila, C1-4 haloalkila, CN, NO2, ORe3, SRe3, C(O)Rf3, C(O)NRg3Rh3, C(O)ORe3, OC(O)Rf3, OC(O)NRg3Rh3, NRg3Rh3, NRg3C(O)Rh3, NRg3C(O)ORe3, C(=NRi)NRg1Rh1, NRg1C(=NRi)NRg1Rh1, P(Rf3)2, P(ORe3)2, P(O)Re3Rf3, P(O)ORe3ORf3, S(O)Rf3, S(O)NRg3Rh3, S(O)2Rf3 i S(O)2NRg3Rh3;Ra i Rb su nezavisno izabrani od H, halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-4 haloalkila, arila, cikloalkila, heteroarila, heterocikloalkila, arilalkila, cikloalkilalkila, heteroarilalkila, heterocikloalkilalkila, CN, NO2, ORe4, SRe4, C(O)Rf4, C(O)NRg4Rh4, C(O)ORe4, OC(O)Rf4, OC(O)NRg4Rh4, NRg4Rh4, NRg4C(O)Rh4, NRg4C(O)ORe4, C(=NRi)NRg1Rh1, NRg1C(=NRi)NRg1Rh1, P(Rf4)2, P(ORe4)2, P(O)Re4Rf4, P(O)ORe4ORf4, S(O)Rf4, S(O)NRg4Rh4, S(O)2Rf4 i S(O)2NRg4Rh4;Rc je H, C1-6 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, cikloalkila, arilalkila ili cikloalkilalkila;Rd je H, ORd1, CN ili NO2;Rd1 je H, C1-6 alkil, C1-6 haloalkil, C2-6 alkenil, C2-6 alkinil, aril, cikloalkil, arilalkil ili cikloalkilalkil;Rel, Re3 i R64 su nezavisno izabrani od H, C1-6 alkila, C1-6 haloalkila, C2-6 alkenila, (C1-6 alkoksi)-C1-6 alkila, C2-6 alkinila, arila, cikloalkila, heteroarila, heterocikloalkila, arilalkila, cikloalkilalkila, heteroarilalkila i heterocikloalkilalkila;Rf1, Rf3 i Rf4 su nezavisno izabrani od H, C1-6 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, cikloalkila, heteroarila i heterocikloalkila;Rg1, Rg3 i Rg4 nezavisno su izabrani od H, C1-6 alkil, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, cikloalkila, arilalkila i cikloalkilalkila;Rh1, Rh3 i Rh4 su nezavisno izabrani od H, C1-6 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, cikloalkila, arilalkila i cikloalkilalkila;ili Rg1 i Rh1 zajedno sa N atomom za koji su vezani formiraju 4-, 5-, 6- ili 7-očlanu heterocikloalkil grupu;ili Rg3 i Rh3 zajedno sa N atomom za koji su vezani formiraju 4-, 5-, 6- ili 7-očlanu heterocikloalkil grupu;ili Rg4 i Rh4 zajedno sa N atomom za koji su vezani formiraju 4-, 5-, 6- ili 7-očlanu heterocikloalkil grupu;Ri je H, CN ili NO2;a je 0 ili 1;b je 0 ili 1;n je 0 ili 1;p je 0 ili 1;t je 1, 2, 3, 4, 5 ili 6;u je 0, 1, 2, 3, 4, 5 ili 6; iv je 0, 1, 2, 3, 4, 5 ili 6.
2. Jedinjenje ili so za upotrebu prema zahtevu 1, pri čemu R2 jeste H.
3. Jedinjenje ili so za upotrebu prema zahtevu 2, pri čemu n jeste 0.
4. Jedinjenje ili so za upotrebu prema zahtevu 3, pri čemu p jeste 1.
5. Jedinjenje ili so za upotrebu prema zahtevu 4, pri čemu R5b jeste H.
6. Jedinjenje ili so za upotrebu prema zahtevu 5, pri čemu a jeste 0.
7. Jedinjenje ili so za upotrebu prema zahtevu 6, pri čemu b jeste 0.
8. Jedinjenje ili so za upotrebu prema zahtevu 7, pri čemu R3b jeste fenil opciono supstituisan sa 1, 2, 3, 4 ili 5 supstituenata nezavisno izabranih od halo, C1-6 alkila, C2-6 alkenila, C1-6 alkinila, C1-4 haloalkila, Cy2, CN, NO2, ORe1, SRe1, C(O)Rf1, C(O)NRg1Rh1, C(O)ORe1, OC(O)Rf1, OC(O)NRg1Rh1, NRg1(O)NRg1Rh1, NRg1Rh1, NRg1C(O)Rf1, NRg1C(O)ORe1, P(Rf1)2, P(ORe1)2, P(O)Re1Rt1, P(O)ORe1ORf1, S(O)Rf1, S(O)NRg1Rh1, S(O)1Rf1 i S(O)2NRg1Rh1.
9. Jedinjenja ili so za upotrebu prema zahtevu 6, pri čemu b jeste 1.
10. Jedinjenja ili so za upotrebu prema zahtevu 9, pri čemu W jeste (CRaRb)t ili (CRaRb)uO(CRaRb)v.
11. Jedinjenje ili so za upotrebu prema zahtevu 10, pri čemu R3b je heteroaril, opciono supstituisan sa 1, 2, 3, 4 ili 5 supstituenata nezavisno izabranih od halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-4 haloalkila, Cy2, CN, NO2, ORe1, SRe1, C(O)Rf1, C(O)NRg1Rh1, C(O)ORe1, OC(O)Rf1, OC(O)NRg1Rh1, NRg1C(O)NRg1Rh1, Ng1Rh1, NRg1C(O)Rf1, NRg1C(O)ORe1 P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORe1ORf1, S(O)Rf1, S(O)NRg1Rh1, S(O)2Rf1 i S(O)2NRg1Rh1.
12. Jedinjenje ili so za upotrebu prema zahtevu 1, pri čemu jedinjenje ima formulu: gde je: X1 (CRaRb)t ili (CRaRb)uC(O)(CRaRb)v; R3a je C1-8 alkil, C2-8 alkenil, C2-8 alkinil, aril, cikloalkil, heteroaril ili heterocikloalkil, svaki opciono supstituisan sa 1, 2, 3, 4 ili 5 supstituenata nezavisno izabranih od halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-4 haloalkila, C1-4 hidroksialkila, Cy1, CN, NO2, ORe1, SRe1, C(O)Rf1, C(O)NRg1Rh1, C(O)ORe1, OC(O)Rf1, OC(O)NRg1Rh1, NRg1C(O)NRg1Rh1, NRg1Rh1, NRg1C(O)Rf1, NRg1C(O)ORe1, C(=NRi)NRg1Rh1, NRg1C(=NRi)NRg1Rh1, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORe1Rf1, S(O)Rf1, S(O)NRg1Rh1, S(O)2Rf1 i S(O)2NRg1Rh1; R3b je aril ili heteroaril, svaki opciono supstituisan sa 1, 2, 3, 4 ili 5 supstituenata nezavisno izabranih od halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-4 haloalkila, C1-4 hidroksialkila, Cy2, CN, NO2, ORe1, SRe1, C(O)Rf1, C(O)NRg1Rh1, C(O)ORe1, OC(O)Rf1, OC(O)NRg1Rh1, NRg1C(O)NRg1Rh1, NRg1Rh1, NRg1C(O)Rf1, NRg1C(O)ORe1, C(=NRi)NRg1Rh1, NRg1C(=NRi)NRg1Rh1, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORe1ORf1, S(O)Rf1, S(O)NRg1Rh1, S(O)2Rf1 i S(O)2NRg1Rh1; R5b je H, C1-8 alkil, C2-8 alkenil, C2-8 alkinil, aril, cikloalkil, heteroaril ili heterocikloalkil; gde su spomenuti C1-8 alkil, C2-8 alkenil, C2-8 alkinil, aril, cikloalkil, heteroaril ili heterocikloalkil svaki opciono supstituisan sa 1, 2, 3, 4 ili 5 supstituenata nezavisno izabranih od halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-4 haloalkila, C1-4 hidroksialkila, Cy2, CN, NO2, ORe1, SRe1, C(O)Rf1, C(O)NRg1Rh1, C(O)ORe1, OC(O)Rf1, OC(O)NRg1Rh1, NRg1C(O)NRg1Rh1, NRg1R , NRg1C(O)Rf1, NRg1C(O)ORe1, C(=NRi)NRg1Rh1, NRg1C(=NRi)NRg1Rh1, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORe10Rf1, S(O)Rf1, S(O)NRg1Rh1, S(O)2Rf1 i S(O)2NRg1Rh1; Cy1 i Cy2 su nezavisno izabrani kao aril, heteroaril, cikloalkil i heterocikloalkil, svaki opciono supstituisan sa 1, 2, 3,4 ili 5 supstituenata nezavisno izabranih od halo, C1-4 alkila, C2-4 alkenila, C2-4 alkinila, C1-4 haloalkila, CN, NO2, ORe3, SRe3, C(O)Rf3, C(O)NRg3Rh3, C(O)ORe3, OC(O)Rf3, OC(O)NRg3Rh3, NRg3Rh3, NRg3C(O)Rh3, NRg3C(O)ORe3, C(=NRi)NRg1Rh1, NRg1C(=NRi)NRg1Rh1, P(Rf3)2, P(ORe3)2, P(O)Re3Rf3, P(O)ORe3ORf3, S(O)Rf3, S(O)NRg3Rh3, S(O)zRf3 i S(O)2NRg3Rh3; Ra i Rb su nezavisno izabrani od H, halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-4 haloalkila, arila, cikloalkila, heteroarila, heterocikloalkila, arilalkila, cikloalkilalkila, heteroarilalkila, heterocikloalkilalkila, CN, NO2, ORe4, SRe4, C(O)Rf4, C(O)NRg4Rh4, C(O)ORe4, OC(O)Rf4, OC(O)NRg4Rh4, NRg4Rh4, NRg4C(O)Rh4, NRg4C(O)ORe4, C(=NRi)NRg1Rh1, NRg1C(=NRi)NRg1Rh1, P(Rf4)2, P(ORe4)2 P(O)Re4Rf4, P(O)ORe4ORf4, S(O)Rf4, S(O)NRg4Rh4, S(O)2Rf4 i S(O)2NRg4Rh4; Re1, Re3 i Re4 su nezavisno izabrani od H, C1-6 alkila, C1-6 haloalkila, C2-6 alkenila, (C1-6 alkoksi)-C1-6 alkila, C2-6 alkinila, arila, cikloalkila, heteroarila, heterocikloalkila, arilalkila, cikloalkilalkila, heteroarilalkila i heterocikloalkilalkila; Rf1, Rf3 i Rf4 su nezavisno izabrani od H, C1-6 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, cikloalkila, heteroarila i heterocikloalkila; Rg1, Rg3 i Rg4 su nezavisno izabrani od H, C1-6 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, cikloalkila, arilalkila i cikloalkilalkila; Rh1, Rh3 i Rh4 su nezavisno izabrani od H, C1-6 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, cikloalkila, arilalkila i cikloalkilalkila; ili Rg1 i Rh1 zajedno sa N atomom za koji su vezani, formiraju 4-, 5-, 6- ili 7-očlanu heterocikloalkil grupu; ili Rg3 i Rh3 zajedno sa N atomom za koji su vezani, formiraju 4-, 5-, 6- ili 7-očlanu heterocikloalkil grupu; ili Rg4 i Rh4 zajedno sa N atomom za koji su vezani, formiraju 4-, 5-, 6- ili 7-očlanu heterocikloalkil grupu; Ri je H, CN ili NO2; a je 0 ili 1; t je 1, 2, 3, 4, 5 ili 6; u je 0, 1, 2, 3, 4, 5 ili 6; i v je 0, 1, 2, 3, 4, 5 ili 6.
13. Jedinjenje ili so za upotrebu prema zahtevu 1, pri čemu je jedinjenje izabrano od: N-benzil-4-(benzilamino)-N’-hidroksi-1,2,5-oksadiazol-3-karboksimidamid; 4-[(anilinokarbonil)amino]-N-(3-hlorofenil)-N’-hidroksi-1,2,5-oksadiazol-3-karboksimidamid; Terc-butil{4-[({4-[(E,Z)-[(3-hlorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}amino)karbonil]benzil} karbamat; 4-(aminometil)-N-{4-[(E,Z)-[(3-hlorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}benzamid; 4-{[(benzilamino)karbonil]amino}-N-(3-bromo-4-fluorofenil)-N’-hidroksi-1,2,5-oksadiazol-3-karboksimidamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}morfolin-4-karboksamid; N-(3-bromo-4-fluorofenil)-N’-hidroksi-4-(metilamino)-1,2,5-oksadiazol-3-karboksimidamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}piperidin-4-karboksamid; Terc-butil4-{4-[({4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}amino) karbonil]benzil}piperazin-1-karboksilat; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-(piperazin-1-ilmetil) benzamid; 1-benzoil-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}piperidin- 4-karboksamid; N(4)-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-N(1)-fenilpiperidin- 1,4-dikarboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1-etilpiperidin-4- karboksamid; 4-[(benzoilamino)metil]-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol- 3-il}benzamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(2-cijanofenoksi) acetamid; N-{4-[(E,Z-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-fenilpiperidin-4-karboksamid; N-(3-bromo-4-fluorofenil)-4-({4-[(1,1-dioksidotiomorfolin-4-il)metil]benzil}amino)-N’-hidroksi-1,2,5-oksadiazol-3-karboksimidamid; N-(3-bromo-4-fluorofenil)-N’-hidroksi-4-{[4-(morfolin-4-ilmetil)benzil]amino}-1,2,5-oksadiazol-3-karboksimidamid; N-(3-cijano-4-fluorofenil)-4-({4-[(1,1-dioksidotiomorfolin-4-il)metil]benzil}amino)-N’-hidroksi-1,2,5-oksadiazol-3-karboksimidamid; N-(3-bromo-4-fluorofenil)-N’-hidroksi-4-[(piridin-3-ilmetil)amino]-1,2,5-oksadiazol-3-karboksimidamid; N-(3-cijano-4-fluorofenil)-N’-hidroksi-4-[(piridin-4-ilmetil)amino]-1,2,5-oksadiazol-3-karboksimidamid; 4-[(3-cijanobenzil)amino]-N-(3-cijano-4-fluorofenil)-N’-hidroksi-1,2,5-oksadiazol-3-karboksimidamid; N-(3-bromo-4-fluorofenil)-N’-hidroksi-4-[(1H-tetrazol-5-ilmetil)amino]-1,2,5-oksadiazol-3-karboksimidamid; N-{4-[(E,Z)-[(3-hlorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}ciklopentankarboksamid; N-{4-[(E,Z)-[(3-hlorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}nikotinamid; N-{4-[(E,Z)-[(3-hlorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il} izonikotinamid; N-{4-[(E,Z-[(3-hlorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-metoksibenzamid; N-{4-[(E,Z)-[(3-hlorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-metoksibenzamid; N-{4-[(E,Z)-[(3-hlorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-metoksibenzamid; 2-hloro-N-{4-[(E,Z)-[(3-hlorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}benzamid; 3-hloro-N-{4-[(E,Z)-[(3-hlorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}benzamid; 4-hloro-N-{4-[(E,Z)-[(3-hlorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}benzamid; N-{4-[(E,Z)-[(3-hlorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3,3-dimetilbutanamid; N-{4-[(E,Z)-[(3-hlorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-jodobenzamid; N-{4-[(E,Z)-[(3-hlorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-cijanobenzamid; N-{4-[(E,Z)-{[4-fluoro-3-(trifluorometil)fenil]amino}(hidroksiimino)metil]-1,2,5-oksadiazol-3-il}nikotinamid; N-{4-[(E,Z-{[4-fluoro-3-(trifluorometil)fenil]amino}(hidroksiimino)metil]-1,2,5-oksadiazol-3-il}izonikotinamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}benzamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}nikotinamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il} izonikotinamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-cijanobenzamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-cijanobenzamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-naftamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1-naftamid; 1-acetil-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}piperidin-4-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-furamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}tiofen-2-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1-fenil-5-(trifluorometil)- 1H-pirazol-4-karboksamid; 4-(acetilamino)-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}benzamid Terc-butil {4-[({4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}amino)karbonil] benzil}karbamat N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1-benzotiofen-2-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1,3-tiazol-4-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1-benzotiofen-3-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}tiofen-3-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1H-imidazol-2-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-metil-1,2,3-tiadiazol-5-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1,2,3-tiadiazol-4-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2,1-benzizoksazol-3-karboksamid; 4-(aminometil)-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}benzamid; N-(3-bromo-4-fluorofenil)-N’-hidroksi-4-({[(2-feniletil)amino]karbonil}amino)-1,2,5-oksadiazol-3-karboksimidamid; N-(3-bromo-4-fluorofenil)-4-{[(ciklopentilamino)karbonil]amino}-N’-hidroksi-1,2,5-oksadiazol-3-karboksimidamid; N-(3-bromo-4-fluorofenil)-4-({[(3-cijanofenil)amino]karbonil}amino)-N’-hidroksi-1,2,5-oksadiazol-3 -karboksimidamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-terc-butil-1-metil-1H-pirazol-5 -karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-metoksiacetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}ciklopentankarboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}butanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-metilpropanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}propanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}cikloheksankarboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1H-benzimidazol-5-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-fenoksiacetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}ciklobutankarboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-metilbutanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-piridin-3-ilpropanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}kinolin-6-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(4-hlorofenoksi)acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(4-bromofenoksi)acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(4-fluorofenoksi)acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(4-terc-butilfenoksi) acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(3-hlorofenoksi)acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(3,4-dihlorofenoksi) acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(2-naftiloksi)acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(2,3-dihlorofenoksi) acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(4-hlorofenoksi)-2-metilpropanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(2-hlorofenoksi)acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(3-metoksifenoksi)acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(4-metoksifenoksi)acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(2-metoksifenoksi)acetamid; Benzil {4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}karbamat; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}piperidin-1-karboksamid; N-(3-bromo-4-fluorofenil)-4-({[(3-cijanofenil)(metil)amino]karbonil}amino)-N’-hidroksi-1,2,5-oksadiazol-3-karboksimidamid; 4-({[benzil(metil)amino]karbonil}amino)-N-(3-bromo-4-fluorofenil)-N’-hidroksi-1,2,5-oksadiazol-3-karboksimidamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-fenilacetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(3-metoksifenil)acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(4-metoksifenil)acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(2-metoksifenil)acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-cijanobenzamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(3-bromofenil)propanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(4-bromofenil)propanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(4-hlorofenil)propanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(3-hlorofenil)propanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(2-fluorofenil)propanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(3-fluorofenil)propanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(2-hlorofenil)propanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(3-metilfenil)propanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(3-(trifluorometil)fenil) propanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(4-fluorofenil)propanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(2-metoksifenil)propanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(3-metoksifenil)propanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(4-metoksifenil)propanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(4-metilfenil)propanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-[4-(trifluorometil)fenil] propanamid; 3-[2,5-bis(trifluorometil)fenil]-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}propanamid; 3-[3,5-bis(trifluorometil)fenil]-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}propanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-metil-3-fenilpropanamid; 2-benzil-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3,3-dimetilbutanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1-[4-(trifluorometil) pirimidin-2-il]piperidin-4-karboksamid; 1-benzil-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-terc-butil-1H-pirazol-5-karboksamid; 2-(benziloksi)-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1-(4-hlorofenil)ciklopentan karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-fenoksibenzamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2,4,6-trihlorobenzamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-metoksibenzamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-metoksibenzamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2,2-difenilacetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-(trifluorometoksi)benzamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-metoksibenzamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3,4-dimetoksibenzamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(2-nitrofenoksi)acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}bifenil-4-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(2,6-dihlorobenzil)-1,3-tiazol-4-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2,6-dimetoksibenzamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-nitrobenzamid; 5-bromo-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}nikotinamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3,3-dimetilbutanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(2-tienil)acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-fenilbutanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2,2-dimetilpropanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-(morfolin-4-ilmetil)benzamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-[(1,1-dioksidotiomorfolin- 4-il)metil]benzamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1-(fenilacetil)piperidin-4-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1-(metilsulfonil)piperidin-4-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-piridin-4-il-1,3-tiazol-4-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-nitrobenzamid; N-(4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-nitrobenzamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1-izopropilpiperidin-4-karboks amid; Terc-butil 4-{4-[({4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}amino)karbonil]-1,3-tiazol-2-il}piperidin-1-karboksilat; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-fenil-1,3-tiazol-4-karboks amid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-metil-1,3-tiazol-4-karboks amid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-piperidin-4-il-1,3-tiazol-4-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(4-cijanofenoksi)acetamid; Terc-butil 3-[({4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}amino)karbonil] piperidin-1-karboksilat; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(3-nitrofenil)propanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(3-nitrofenoksi)acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(4-nitrofenoksi)acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}piperidin-3-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-metil-2-piridin-3-il-1,3-tiazol-5-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-metil-1,3-tiazol-5-karboks amid; 2-amino-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1,3-tiazol-4-karboks amid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-metil-2-pirazin-2-il-1,3-tiazol-5-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-metil-2-[4-(trifluorometil) fenil]-1,3-tiazol-5-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2,4-dimetil-1,3-tiazol-5-karboksamid; 1-acetil-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}pirolidin-2-karboks amid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1,5-dimetil-1H-pirazol-3-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-5-hloro-1-metil-1H-pirazol-4-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1,3-dimetil-1H-pirazol-5-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1-metil-1H-imidazol-2-karboksamid; 4-[(acetilamino)metil]-N-{4-[(E,Z-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3- il}benzamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-metilpiperidin-4-karboks amid; 1-acetil-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}piperidin-3-karboks amid; 1-acetil-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-metilpiperidin- 4-karboksamid; 1-acetil-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-fenilpiperidin- 4-karboksamid; 4-(benzilamino)-N-(3-bromo-4-fluorofenil)-N’-hidroksi-1,2,5-oksadiazol-3-karboksimidamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1-etilpiperidin-3-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-etilpiperazin-1-karboksamid; 4-acetil-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}piperazin-1-karboks amid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(1-etilpiperidin- 4-il)-1,3-tiazol-4-karboksamid; N-(3-bromo-4-fluorofenil)-N’-hidroksi-4-[(1,3-tiazol-4-ilmetil)amino]-1,2,5-oksadiazol-3-karboksimidamid; N-(3-bromo-4-fluorofenil)-4-[(4-cijanobenzil)amino]-N’-hidroksi-1,2,5-oksadiazol-3-karboksimidamid; N-(3-bromo-4-fluorofenil)-N’-hidroksi-4-{[(1-metilpiperidin-4-il)metil]amino}-1,2,5-oksadiazol-3 -karboksimidamid; N-(3-bromo-4-fluorofenil)-N’-hidroksi-4-{[4-(piperazin-1-ilmetil)benzil]amino}-1,2,5-oksadiazol-3-karboksimidamid; N-(3-bromo-4-fluorofenil)-4-({4-[(4-etilpiperazin-1-il)metil]benzil}amino)-N’-hidroksi-1,2,5-oksadiazol-3-karboksimid amid; N-(3-bromo-4-fluorofenil)-N’-hidroksi-4-[(piridin-4-ilmetil)amino]-1,2,5-oksadiazol-3-karboksimidamid; i N-(3-bromo-4-fluorofenil)-4-[(3-cijanobenzil)amino]-N’-hidroksi-1,2,5-oksadiazol-3-karboksimidamid; N-{4-[[(3-hlorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-fenilacetamid; N-{4-[[(3-hlorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}benzamid; i N-{4-[(benzilamino)(hidroksiimino)metil]-1,2,5-oksadiazol-3-il}benzamid; ili njihove farmaceutski prihvatljive soli.
14. Jedinjenje ili so za upotrebu prema zahtevu 1, pri čemu je spomenuti kancer izabran od kancera debelog creva, pankreasa, kancera dojke, kancera prostate, kancera pluća, kancera mozga, kancera jajnika, cervikalnog kancera, kancera testisa, kancera bubrega, kancera glave i vrata, limfoma, leukemije i melanoma.
MEP-2016-96A 2005-05-10 2006-05-09 Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih ME02461B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67950705P 2005-05-10 2005-05-10
EP12178315.3A EP2559690B1 (en) 2005-05-10 2006-05-09 Modulators of indoleamine 2,3-dioxygenase and methods of using the same

Publications (1)

Publication Number Publication Date
ME02461B true ME02461B (me) 2017-02-20

Family

ID=37396891

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2016-96A ME02461B (me) 2005-05-10 2006-05-09 Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih

Country Status (32)

Country Link
US (6) US8034953B2 (me)
EP (3) EP2559690B1 (me)
JP (2) JP4990270B2 (me)
KR (2) KR101562549B1 (me)
CN (2) CN101212967A (me)
AR (1) AR054271A1 (me)
AU (1) AU2006244068B9 (me)
BR (2) BR122020016659B8 (me)
CA (1) CA2606783C (me)
CR (1) CR9485A (me)
CY (2) CY1113989T1 (me)
DK (2) DK1879573T3 (me)
EA (1) EA026785B1 (me)
ES (2) ES2578404T3 (me)
GE (1) GEP20217221B (me)
HR (2) HRP20130220T1 (me)
HU (1) HUE029214T2 (me)
IL (2) IL186957A (me)
ME (1) ME02461B (me)
MX (1) MX2007013977A (me)
MY (1) MY153424A (me)
NO (2) NO340487B1 (me)
NZ (1) NZ562919A (me)
PL (2) PL1879573T3 (me)
PT (2) PT1879573E (me)
RS (2) RS52711B (me)
SG (3) SG195607A1 (me)
SI (2) SI2559690T1 (me)
TW (1) TWI377060B (me)
UA (1) UA99897C2 (me)
WO (1) WO2006122150A1 (me)
ZA (1) ZA200709698B (me)

Families Citing this family (266)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0307077A2 (pt) * 2002-01-22 2017-06-20 Biomatera Inc método para secar polímeros biodegradáveis
WO2006082030A1 (en) * 2005-02-04 2006-08-10 Ctg Pharma S.R.L. New 4-aminoquinoline derivatives as antimalarials
CN101218254A (zh) 2005-02-14 2008-07-09 惠氏公司 白介素-17f抗体及其它il-17f信号传递拮抗剂和它们的用途
DK1879573T3 (da) 2005-05-10 2013-02-25 Incyte Corp Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf
GB0512091D0 (en) * 2005-06-14 2005-07-20 Novartis Ag Organic compounds
DE102005053947A1 (de) * 2005-11-11 2007-05-16 Univ Ernst Moritz Arndt Neue Arzneimittel
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
US20070203140A1 (en) * 2006-02-09 2007-08-30 Combs Andrew P N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
BRPI0719122A2 (pt) 2006-08-24 2013-12-10 Novartis Ag Compostos orgânicos
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
CA2663057C (en) 2006-09-19 2015-12-08 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US20080146624A1 (en) * 2006-09-19 2008-06-19 Incyte Corporation Amidines as modulators of indoleamine 2,3-dioxygenase
MX2009003080A (es) 2006-09-22 2009-04-02 Novartis Ag Compuestos organicos heterociclicos.
US20080182882A1 (en) * 2006-11-08 2008-07-31 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
AU2007336238A1 (en) 2006-12-20 2008-06-26 Novartis Ag 2-substituted 5-membered heterocycles as SCD inhibitors
EP2137168B1 (en) * 2007-03-16 2016-09-14 Lankenau Institute for Medical Research Novel ido inhibitors and methods of use thereof
US20090170842A1 (en) * 2007-11-14 2009-07-02 University Of Kansas Brca1-based breast or ovarian cancer prevention agents and methods of use
WO2009073620A2 (en) 2007-11-30 2009-06-11 Newlink Genetics Ido inhibitors
US20090253706A1 (en) * 2008-04-03 2009-10-08 Muller Alexander J Methods and Compositions for the Treatment of Rheumatoid Arthritis and Other Inflammatory Diseases
DK2280721T3 (da) 2008-04-17 2018-01-29 Io Biotech Aps Indoleamin-2, 3-dioxygenasebaseret immunterapi
CA3012229C (en) 2008-07-08 2020-11-10 Incyte Holdings Corporation 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
UA107672C2 (en) 2009-09-25 2015-02-10 Bayer Cropscience Ag N-(1,2,5-oxadiazol-3-yl)benzamides and the use thereof as herbicides
JP2012041325A (ja) * 2010-08-23 2012-03-01 Bayer Cropscience Ag オキサジアゾリノン誘導体およびその有害生物の防除用途
WO2012087234A1 (en) 2010-12-22 2012-06-28 Idogen Ab A composition comprising at least to compounds which induces indolamine 2,3-dioxygenase (ido), for the treatment of an autoimmune disorder or suffering from immune rejection of organs
NO2694640T3 (me) 2011-04-15 2018-03-17
KR20140098140A (ko) 2011-11-16 2014-08-07 바스프 에스이 치환 1,2,5-옥사디아졸 화합물 및 이들의 제초제 ｉｉ 로서의 용도
AU2012338748A1 (en) * 2011-11-18 2014-06-05 Basf Se Substituted 1,2,5-oxadiazole compounds and their use as herbicides III
KR101229365B1 (ko) * 2012-07-02 2013-02-18 대한민국 〔ｚ〕­ｎ­〔３­〔２，４­디플루오로페닐아미노〕­１­〔４­나이트로페닐〕­３­옥소프로프­１­엔­２­일〕­２­메톡시벤즈아마이드를 유효성분으로 함유하는 신경퇴행성 질환 예방 및 치료용 약학적 조성물
CA2889182A1 (en) 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
CN105377812B (zh) 2013-06-21 2018-09-18 组合化学工业株式会社 2-氨基-2-肟基-n-烷氧基亚氨代乙酰基氰化物的制备方法及其制备中间体
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
RU2536041C1 (ru) * 2013-10-11 2014-12-20 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ НАУКИ ИНСТИТУТ ОРГАНИЧЕСКОЙ ХИМИИ им. Н.Д. ЗЕЛИНСКОГО РОССИЙСКОЙ АКАДЕМИИ НАУК (ИОХ РАН) 3,3'-бис(фтординитрометил-onn-азокси)-4,4'-дифуразаниловый эфир и способ его получения
EP3744715A1 (en) * 2013-11-08 2020-12-02 Incyte Holdings Corporation Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor
CN103570727B (zh) 2013-11-12 2015-08-19 复旦大学 一种n-苄基色胺酮衍生物及其制备方法和应用
EA201990240A1 (ru) 2013-12-24 2019-06-28 Бристол-Маерс Сквибб Компани Новые трициклические соединения в качестве противораковых средств
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
JP2017525753A (ja) * 2014-06-06 2017-09-07 フレクサス・バイオサイエンシーズ・インコーポレイテッドＦｌｅｘｕｓ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． 免疫調節剤
PL3151921T3 (pl) 2014-06-06 2020-02-28 Bristol-Myers Squibb Company Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
WO2016024233A1 (en) * 2014-08-13 2016-02-18 Auckland Uniservices Limited Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
GB201414730D0 (en) 2014-08-19 2014-10-01 Tpp Global Dev Ltd Pharmaceutical compound
WO2016040458A2 (en) * 2014-09-09 2016-03-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Pet probes of radiofluorinated carboximidamides for ido-targeted imaging
CN105481789B (zh) * 2014-09-15 2020-05-19 中国科学院上海有机化学研究所 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法
EA201790806A1 (ru) 2014-11-05 2017-11-30 Флексус Байосайенсиз, Инк. Иммунорегулирующие средства
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
AR102537A1 (es) 2014-11-05 2017-03-08 Flexus Biosciences Inc Agentes inmunomoduladores
JP6805142B2 (ja) 2014-11-21 2020-12-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｄ７３に対する抗体およびその使用
WO2016100851A1 (en) 2014-12-18 2016-06-23 Lankenau Institute For Medical Research Methods and compositions for the treatment of retinopathy and other ocular diseases
AR103232A1 (es) 2014-12-22 2017-04-26 Bristol Myers Squibb Co ANTAGONISTAS DE TGFbR
AR103268A1 (es) 2014-12-23 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra tigit
WO2016127052A1 (en) 2015-02-05 2016-08-11 Bristol-Myers Squibb Company Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
JP6836998B2 (ja) 2015-03-02 2021-03-03 ライジェル ファーマシューティカルズ， インコーポレイテッド ＴＧＦ−β阻害剤
MX2017012738A (es) 2015-04-03 2017-11-15 Bristol Myers Squibb Co Inhibidores de indolamina 2.3-dioxigenasa (ido) para el tratamiento de cancer.
WO2016162505A1 (en) 2015-04-08 2016-10-13 F-Star Biotechnology Limited Her2 binding agent therapies
CA2980460A1 (en) 2015-04-13 2016-10-20 Five Prime Therapeutics, Inc. Combination therapy for cancer
CN106715440B (zh) 2015-04-21 2019-02-22 江苏恒瑞医药股份有限公司 咪唑并异吲哚类衍生物、其制备方法及其在医药上的应用
WO2016183114A1 (en) 2015-05-11 2016-11-17 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
WO2016183115A1 (en) 2015-05-12 2016-11-17 Bristol-Myers Squibb Company 5h-pyrido[3,2-b]indole compounds as anticancer agents
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
EP3294324A1 (en) 2015-05-13 2018-03-21 Agenus Inc. Vaccines for treatment and prevention of cancer
AU2016271111B2 (en) 2015-05-29 2022-04-28 Bristol-Myers Squibb Company Antibodies against OX40 and uses thereof
MX2017016502A (es) 2015-06-29 2018-03-12 Univ Rockefeller Anticuerpos contra cd40 con actividad agonista mejorada.
WO2017002078A1 (en) * 2015-07-02 2017-01-05 Glaxosmithkline Intellectual Property Development Limited Inhibitors of indoleamine 2,3-dioxygenase
GB201511790D0 (en) 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound
US20180271861A1 (en) 2015-07-14 2018-09-27 Kyowa Hakko Kirin Co., Ltd. Therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
MX2017016844A (es) 2015-07-16 2018-08-15 Biokine Therapeutics Ltd Composiciones y procedimientos para tratar cancer.
PE20180928A1 (es) 2015-07-24 2018-06-08 Newlink Genetics Corp Sales y profarmacos de 1-metil-d-triptofano
US10399987B2 (en) 2015-07-28 2019-09-03 Bristol-Myer Squibb Company TGF beta receptor antagonists
CN108349976A (zh) 2015-08-25 2018-07-31 百时美施贵宝公司 TGFβ受体拮抗剂
CN106565696B (zh) * 2015-10-09 2020-07-28 江苏恒瑞医药股份有限公司 噁二唑类衍生物、其制备方法及其在医药上的应用
CA3001131A1 (en) 2015-11-02 2017-05-11 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides and their use in cancer treatment
PT3370768T (pt) 2015-11-03 2022-04-21 Janssen Biotech Inc Anticorpos que se ligam especificamente ao pd-1 e seus usos
CN108472245A (zh) 2015-11-04 2018-08-31 因赛特公司 用于吲哚胺2,3-双加氧酶抑制及其适应症的药物组合物和方法
MX2018006072A (es) 2015-11-19 2018-08-01 Squibb Bristol Myers Co Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
SG10201913538VA (en) 2015-11-23 2020-02-27 Five Prime Therapeutics Inc Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
JP6411676B2 (ja) 2015-12-03 2018-10-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｓｔｉｎｇの調節因子としての環状プリンジヌクレオチド
US10450318B2 (en) 2015-12-15 2019-10-22 Bristol-Myers Squibb Company CXCR4 receptor antagonists
CN106883193B (zh) * 2015-12-15 2021-10-15 上海翰森生物医药科技有限公司 吲哚胺2,3-双加氧酶抑制剂及其制备方法与应用
EP3389783B1 (en) 2015-12-15 2024-07-03 Merck Sharp & Dohme LLC Novel compounds as indoleamine 2,3-dioxygenase inhibitors
CN106883194A (zh) * 2015-12-16 2017-06-23 江苏恒瑞医药股份有限公司 噁二唑类衍生物、其制备方法及其在医药上的应用
US9624185B1 (en) * 2016-01-20 2017-04-18 Yong Xu Method for preparing IDO inhibitor epacadostat
CN105646389B (zh) * 2016-01-28 2019-06-28 中国科学院上海有机化学研究所 一种作为吲哚胺-2,3-双加氧酶抑制剂的氨基磺酸脂及其制备方法和用途
WO2017134555A1 (en) 2016-02-02 2017-08-10 Emcure Pharmaceuticals Limited Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
CN107033097B (zh) * 2016-02-04 2022-02-08 江苏恒瑞医药股份有限公司 噁二唑类衍生物、其制备方法及其在医药上的应用
WO2017140272A1 (zh) * 2016-02-19 2017-08-24 正大天晴药业集团股份有限公司 作为免疫调节剂的三并环化合物
EP3416725A1 (en) * 2016-02-19 2018-12-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of obesity
WO2017149469A1 (en) 2016-03-03 2017-09-08 Emcure Pharmaceuticals Limited Heterocyclic compounds useful as ido and/or tdo modulators
AU2017228470A1 (en) 2016-03-04 2018-08-30 Bristol-Myers Squibb Company Combination therapy with anti-CD73 antibodies
CN107176933B (zh) * 2016-03-09 2020-10-09 中国科学院上海有机化学研究所 一种含氮烷基化和芳基化亚砜亚胺的吲哚胺-2,3-双加氧酶抑制剂
WO2017175156A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
SG10201900628RA (en) 2016-04-07 2019-02-27 Glaxosmithkline Ip Dev Ltd Heterocyclic amides useful as protein modulators
BR112018071307A2 (pt) 2016-04-18 2019-02-26 Celldex Therapeutics, Inc. anticorpos agonistas que ligam cd40 humana e usos dos mesmos
CN107304191B (zh) * 2016-04-20 2023-09-29 上海翰森生物医药科技有限公司 吲哚胺2,3-双加氧酶抑制剂及其制备方法与应用
WO2017181849A1 (zh) * 2016-04-20 2017-10-26 江苏豪森药业集团有限公司 吲哚胺2,3-双加氧酶抑制剂及其制备方法与应用
EP3452450A1 (en) * 2016-05-04 2019-03-13 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10544099B2 (en) 2016-05-04 2020-01-28 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
EP3452452A4 (en) * 2016-05-04 2019-10-30 Bristol-Myers Squibb Company INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE AND METHOD FOR THEIR USE
EP3452451A4 (en) 2016-05-04 2019-11-13 Bristol-Myers Squibb Company INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
WO2017192844A1 (en) 2016-05-04 2017-11-09 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
JOP20170131B1 (ar) * 2016-06-10 2021-08-17 Lilly Co Eli مركبات 1-تيترا هيدروبيرانييل كاربونيل -2،3-ديهيدرو -1 h- اندول لعلاج السرطان
US20190248893A1 (en) 2016-07-14 2019-08-15 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
CN109789135A (zh) 2016-07-20 2019-05-21 葛兰素史密斯克莱知识产权发展有限公司 作为perk抑制剂的异喹啉衍生物
US20190292179A1 (en) 2016-07-21 2019-09-26 Bristol-Myers Squibb Company TGF Beta RECEPTOR ANTAGONISTS
US20190169140A1 (en) * 2016-08-02 2019-06-06 Shandong Luye Pharmaceutical Co., Ltd. Ido1 inhibitor and preparation method and application thereof
WO2018039430A1 (en) * 2016-08-24 2018-03-01 H. Lee Moffitt Cancer Center & Research Institute, Inc. Radiofluorinated carboximidamides as ido targeting pet tracer for cancer imaging
EP3503916A1 (en) 2016-08-26 2019-07-03 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10988487B2 (en) 2016-08-29 2021-04-27 Merck Sharp & Dohme Corp. Substituted n′-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
EP4268838B1 (en) 2016-09-19 2026-07-29 University Of South Florida Method of targeting oncolytic viruses to tumors
EP3515914A4 (en) 2016-09-24 2020-04-15 BeiGene, Ltd. INNOVATIVE 5- OR 8-SUBSTITUTED IMIDAZO [1,5-A] PYRIDINE AS SELECTIVE INHIBITORS OF INDOLEAMINE AND / OR TRYPTOPHANE-2,3-DIOXYGENASES
CN107954999B (zh) * 2016-10-17 2023-01-24 上海医药集团股份有限公司 含噁二唑环化合物、制备方法、中间体、组合物及应用
UY37466A (es) 2016-11-03 2018-01-31 Phenex Discovery Verwaltungs Gmbh N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
US11168078B2 (en) 2016-11-28 2021-11-09 Shanghai Fochon Pharmaceutical Co., Ltd. Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2,3-dioxygenase
CN106883224B (zh) * 2017-01-03 2019-10-22 中国药科大学 苯并含氮杂环类吲哚胺-2,3-双加氧酶1抑制剂及其用途
CN106866648B (zh) * 2017-01-03 2019-10-22 中国药科大学 邻苯二甲酰亚胺类吲哚胺-2,3-双加氧酶1抑制剂及其用途
US10961239B2 (en) 2017-01-05 2021-03-30 Bristol-Myers Squibb Company TGF beta receptor antagonists
WO2018136437A2 (en) 2017-01-17 2018-07-26 Tesaro, Inc. Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
CN106866571B (zh) * 2017-01-20 2018-06-29 中国药科大学 杂环脲类化合物及其药物组合物和应用
US10927086B2 (en) * 2017-02-24 2021-02-23 Merck Sharp & Dohme Corp. Substituted sulfoximine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
CN110461326A (zh) * 2017-03-29 2019-11-15 默沙东公司 作为吲哚胺2,3-双加氧酶(ido)抑制剂的新型经取代n’-羟基甲脒基-1,2,5-噁二唑化合物
CN106967004B (zh) * 2017-03-29 2019-09-17 中国药科大学 含脲基的ido1和ido2双重抑制剂、其制法及其医药用途
EP3601353A1 (en) 2017-03-31 2020-02-05 Five Prime Therapeutics, Inc. Combination therapy for cancer using anti-gitr antibodies
CN108689958B (zh) * 2017-04-05 2021-09-17 南京华威医药科技集团有限公司 一种含有肼基的吲哚胺2,3-双加氧化酶抑制剂
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
MX2019012431A (es) 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
CN108727361A (zh) * 2017-04-24 2018-11-02 南京药捷安康生物科技有限公司 吲哚胺2,3-双加氧酶抑制剂与应用
CN108794423B (zh) * 2017-04-27 2022-07-19 鲁南制药集团股份有限公司 亚氨脲衍生物
CN110546509A (zh) 2017-04-28 2019-12-06 戊瑞治疗有限公司 用cd80细胞外结构域多肽进行治疗的方法
WO2018209049A1 (en) 2017-05-12 2018-11-15 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN109081818B (zh) * 2017-06-14 2022-04-22 南京华威医药科技集团有限公司 新型吲哚胺2,3-双加氧化酶抑制剂
CN109111438B (zh) * 2017-06-26 2021-11-02 正大天晴药业集团股份有限公司 用于ido抑制剂的脒类化合物
KR102630575B1 (ko) 2017-06-30 2024-01-29 브리스톨-마이어스 스큅 컴퍼니 Ido 억제제의 무정형 및 결정질 형태
CN110891942B (zh) * 2017-07-14 2022-06-07 四川科伦博泰生物医药股份有限公司 噁二唑类衍生物、其制备方法及其在医药上的应用
WO2019021208A1 (en) 2017-07-27 2019-01-31 Glaxosmithkline Intellectual Property Development Limited USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
WO2019023459A1 (en) 2017-07-28 2019-01-31 Bristol-Myers Squibb Company CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
CN111163766A (zh) 2017-08-17 2020-05-15 医肯纳肿瘤学公司 Ahr抑制剂和其用途
US12053505B2 (en) 2017-08-31 2024-08-06 Multimmune Gmbh Hsp70 based combination therapy
JP7208225B2 (ja) 2017-08-31 2023-01-18 ブリストル－マイヤーズ スクイブ カンパニー 抗癌剤としての環状ジヌクレオチド
EP3676277A1 (en) 2017-08-31 2020-07-08 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
US10947263B2 (en) 2017-08-31 2021-03-16 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019042451A1 (zh) * 2017-09-01 2019-03-07 南京药捷安康生物科技有限公司 氘代的吲哚胺2,3-双加氧酶抑制剂及其应用
CN108863976B (zh) * 2017-09-11 2022-09-16 郑州泰基鸿诺医药股份有限公司 用作ido调节剂的化合物及其应用
EP4176876A1 (en) 2017-09-14 2023-05-10 Lankenau Institute for Medical Research Methods and compositions for the treatment of cancer
US11377440B2 (en) 2017-10-05 2022-07-05 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (STING)
AU2018344902B2 (en) 2017-10-05 2021-06-03 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (STING) useful in treating HIV
WO2019074749A1 (en) * 2017-10-09 2019-04-18 Merck Sharp & Dohme Corp. NOVEL SUBSTITUTED CYCLOBUTYLPYRIMIDINE AND CYCLOBUTYLPYRIMIDINE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO)
WO2019074822A1 (en) 2017-10-09 2019-04-18 Bristol-Myers Squibb Company INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
EP3694502B1 (en) * 2017-10-09 2023-08-02 Merck Sharp & Dohme LLC Novel substituted cyclobutylbenzene compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
US11203592B2 (en) 2017-10-09 2021-12-21 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11660311B2 (en) 2017-10-10 2023-05-30 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
ES2997757T3 (en) 2017-10-16 2025-02-18 Bristol Myers Squibb Co Cyclic dinucleotides as anticancer agents
CN109678813A (zh) * 2017-10-18 2019-04-26 中国科学院上海有机化学研究所 吲哚胺-2,3-双加氧酶抑制剂盐及其制备方法
US11603410B2 (en) 2017-11-01 2023-03-14 Bristol-Myers Squibb Company Immunostimulatory agonistic antibodies for use in treating cancer
WO2019090198A1 (en) 2017-11-06 2019-05-09 Bristol-Myers Squibb Company Isofuranone compounds useful as hpk1 inhibitors
CN109748911B (zh) * 2017-11-06 2022-03-11 中国药科大学 一种含三氮唑的ido抑制剂、其制备方法及其医药用途
CN107987031A (zh) * 2017-12-01 2018-05-04 华东理工大学 一种靶向吲哚胺-2,3-双加氧酶1氮芥类抑制剂及其制备方法和应用
US20200352931A1 (en) 2017-12-12 2020-11-12 Phenex Discovery Verwaltungs-GmbH Oxalamides as modulators of indoleamine 2,3-dioxygenase
CN108003111A (zh) * 2017-12-14 2018-05-08 华东理工大学 一种hdac1和ido1双靶点抑制剂及其制备方法和应用
CN109942565B (zh) * 2017-12-20 2021-03-26 海创药业股份有限公司 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法和用途
CN111788227B (zh) 2017-12-27 2025-02-25 百时美施贵宝公司 抗cd40抗体及其用途
AU2019205904A1 (en) 2018-01-05 2020-06-18 Dicerna Pharmaceuticals, Inc. Reducing beta-catenin and IDO expression to potentiate immunotherapy
US11447449B2 (en) 2018-01-05 2022-09-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
JP7358361B2 (ja) 2018-01-12 2023-10-10 ブリストル－マイヤーズ スクイブ カンパニー Ｔｉｍ３に対する抗体およびその使用
CN110054622B (zh) * 2018-01-18 2021-02-23 四川科伦博泰生物医药股份有限公司 噁二唑类衍生物、其制备方法及其在医药上的应用
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
CN108586378B (zh) 2018-01-22 2020-06-19 南京华威医药科技集团有限公司 吲哚胺2,3-双加氧化酶抑制剂及其制备方法和用途
CN110092750B (zh) 2018-01-29 2023-07-21 北京诺诚健华医药科技有限公司 五氟硫烷基取代的酰胺类化合物、其制备方法及其在医药学上的应用
US10519187B2 (en) 2018-02-13 2019-12-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
CN110156674A (zh) * 2018-02-13 2019-08-23 中国科学院上海有机化学研究所 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物
JP7250808B2 (ja) 2018-03-08 2023-04-03 ブリストル－マイヤーズ スクイブ カンパニー 抗がん剤としての環状ジヌクレオチド
SG11202008593PA (en) 2018-03-21 2020-10-29 Five Prime Therapeutics Inc ANTIBODIES BINDING TO VISTA AT ACIDIC pH
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル－マイヤーズ スクイブ カンパニー Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
EP3774755B1 (en) 2018-03-29 2022-05-18 Phenex Discovery Verwaltungs-GmbH Spirocyclic compounds as modulators of indoleamine 2,3-dioxygenase
CA3096674A1 (en) 2018-04-12 2019-10-17 Bristol-Myers Squibb Company Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
US20190314324A1 (en) 2018-04-13 2019-10-17 The University Of Chicago Combination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy
CN112292128A (zh) 2018-04-16 2021-01-29 阿瑞斯医疗有限公司 Ep4抑制剂和其用途
WO2019206800A1 (en) 2018-04-24 2019-10-31 Phenex Discovery Verwaltungs-GmbH Spirocyclic compounds as modulators of indoleamine 2,3-dioxygenase
US12037323B2 (en) 2018-05-03 2024-07-16 Bristol-Myers Squibb Company Uracil derivatives as Mer-AXL inhibitors
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
CN110526898A (zh) 2018-05-25 2019-12-03 北京诺诚健华医药科技有限公司 3-吲唑啉酮类化合物、其制备方法及其在医药学上的应用
GB201809050D0 (en) 2018-06-01 2018-07-18 E Therapeutics Plc Modulators of tryptophan catabolism
CN112654621B (zh) 2018-06-27 2024-05-14 百时美施贵宝公司 可作为t细胞活化剂的经取代萘啶酮化合物
SG11202012973RA (en) 2018-06-27 2021-01-28 Bristol Myers Squibb Co Naphthyridinone compounds useful as t cell activators
MY201995A (en) 2018-07-09 2024-03-28 Five Prime Therapeutics Inc Antibodies binding to ilt4
AU2019301120A1 (en) 2018-07-11 2021-02-25 Bristol-Myers Squibb Company Antibodies binding to VISTA at acidic pH
EP3823604A4 (en) 2018-07-17 2022-03-16 Board of Regents, The University of Texas System COMPOUNDS AS INHIBITORS OF INDOLAMINE-2,3-DIOXYGENASE AND/OR TRYPTOPHANE DIOXYGENASE
WO2020023356A1 (en) 2018-07-23 2020-01-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US12059420B2 (en) 2018-07-23 2024-08-13 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10959986B2 (en) 2018-08-29 2021-03-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11253525B2 (en) 2018-08-29 2022-02-22 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
EP3863722A2 (en) 2018-10-10 2021-08-18 Tilos Theapeutics, Inc. Anti-lap antibody variants and uses thereof
MX2021005708A (es) 2018-11-16 2021-09-21 Bristol Myers Squibb Co Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.
AR117200A1 (es) * 2018-11-30 2021-07-21 Syngenta Participations Ag Derivados de tiazol microbiocidas
CN111689952A (zh) * 2019-03-14 2020-09-22 复旦大学 含硫代四元环结构的2,3-双加氧酶抑制剂及其制备方法和用途
CN111909107B (zh) * 2019-05-10 2023-02-03 药康众拓(江苏)医药科技有限公司 Ido/hdac双重抑制剂及其药物组合物和应用
WO2020231713A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
WO2020231766A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
CN111943906B (zh) * 2019-05-14 2023-12-15 中国医学科学院药物研究所 脒类衍生物、及其制法和药物组合物与用途
JP2022533390A (ja) 2019-05-16 2022-07-22 スティングセラ インコーポレイテッド オキソアクリジニル酢酸誘導体および使用方法
US20220251079A1 (en) 2019-05-16 2022-08-11 Stingthera, Inc. Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
CN112062732B (zh) * 2019-06-10 2023-10-24 鲁南制药集团股份有限公司 一种ido抑制剂及其组合物、制备方法和用途
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
US20220306630A1 (en) 2019-08-06 2022-09-29 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
CA3149719A1 (en) 2019-09-19 2021-03-25 Bristol-Myers Squibb Company Antibodies binding to vista at acidic ph
JP7629459B2 (ja) 2019-11-19 2025-02-13 ブリストル－マイヤーズ スクイブ カンパニー Ｈｅｌｉｏｓタンパク質の阻害剤として有用な化合物
CA3159071A1 (en) 2019-11-26 2021-06-03 Tamar I. ROSENBAUM Salts/cocrystals of (r)-n-(4-chlorophenyl)-2-((1s,4s)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide
AU2020394424A1 (en) 2019-11-26 2022-06-16 Ikena Oncology, Inc. Polymorphic carbazole derivatives and uses thereof
WO2021119753A1 (en) 2019-12-18 2021-06-24 Ctxt Pty Limited Compounds
JP7677976B2 (ja) 2019-12-23 2025-05-15 ブリストル－マイヤーズ スクイブ カンパニー Ｔ細胞アクティベーターとして有用な置換ヘテロアリール化合物
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
MX2022007369A (es) 2019-12-23 2022-07-12 Bristol Myers Squibb Co Compuestos de quinolinonilo piperazina sustituidos utiles como activadores de celulas t.
CA3162979A1 (en) 2019-12-23 2021-07-01 Upender Velaparthi Substituted piperazine derivatives useful as t cell activators
IL294148A (en) 2019-12-23 2022-08-01 Bristol Myers Squibb Co Substituted quinazolinyl compounds are useful as t-cell activators
CN111138425A (zh) * 2020-01-06 2020-05-12 中国药科大学 三氮唑类衍生物及其制备方法与用途
BR112022013424A2 (pt) 2020-01-06 2022-12-13 Hifibio Hk Ltd Anticorpo anti-tnfr2 e seus usos
AU2021205143A1 (en) 2020-01-07 2022-07-28 Hifibio, Inc. Anti-Galectin-9 antibody and uses thereof
EP4090663A1 (en) 2020-01-15 2022-11-23 Blueprint Medicines Corporation Map4k1 inhibitors
US20230140384A1 (en) 2020-03-09 2023-05-04 Bristol-Myers Squibb Company Antibodies to cd40 with enhanced agonist activity
TW202140441A (zh) 2020-03-23 2021-11-01 美商必治妥美雅史谷比公司 經取代之側氧基異吲哚啉化合物
EP4132971A1 (en) 2020-04-09 2023-02-15 Merck Sharp & Dohme LLC Affinity matured anti-lap antibodies and uses thereof
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
WO2021258010A1 (en) 2020-06-19 2021-12-23 Gossamer Bio Services, Inc. Oxime compounds useful as t cell activators
KR20230077722A (ko) 2020-08-10 2023-06-01 지브이20 테라퓨틱스 엘엘씨 Igsf8을 표적화하여 자가면역 질환 및 암을 치료하기 위한 조성물 및 방법
EP4228764A1 (en) 2020-10-14 2023-08-23 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
AU2021400725A1 (en) 2020-12-16 2023-08-03 Gossamer Bio Services, Inc. Compounds useful as t cell activators
WO2022169921A1 (en) 2021-02-04 2022-08-11 Bristol-Myers Squibb Company Benzofuran compounds as sting agonists
MX2023009379A (es) 2021-02-12 2023-10-10 Hoffmann La Roche Derivados de tetrahidroazepina biciclicos para el tratamiento del cancer.
CN113105366B (zh) * 2021-03-04 2022-05-24 中国药科大学 一类含苯基羟肟结构衍生物及其制法与用途
JP2024510176A (ja) 2021-03-08 2024-03-06 ブループリント メディシンズ コーポレイション Ｍａｐ４ｋ１阻害剤
US11918582B2 (en) 2021-03-15 2024-03-05 Rapt Therapeutics, Inc. Pyrazole pyrimidine compounds and uses thereof
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
EP4320125A1 (en) 2021-04-05 2024-02-14 Bristol-Myers Squibb Company Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer
PE20231941A1 (es) 2021-04-06 2023-12-05 Bristol Myers Squibb Co Compuestos de oxoisoindolina sustituidos con piridinilo
MX2024000751A (es) 2021-07-14 2024-03-25 Blueprint Medicines Corp Compuestos heterociclicos como inhibidores de map4k1.
US20240336630A1 (en) 2021-07-15 2024-10-10 Blueprint Medicines Corporation Map4k1 inhibitors
WO2023122777A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
WO2023122772A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
WO2023122778A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Pyridazinone derivatives useful as t cell activators
CN118946556A (zh) 2022-02-01 2024-11-12 阿维纳斯运营公司 Dgk靶向化合物及其用途
KR20250046309A (ko) 2022-08-08 2025-04-02 브리스톨-마이어스 스큅 컴퍼니 T 세포 활성화제로서 유용한 치환된 테트라졸릴 화합물
US20260049076A1 (en) 2022-08-09 2026-02-19 Bristol-Myers Squibb Company Tertiary Amine Substituted Bicyclic Compounds Useful as T Cell Activators
WO2024033458A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydroazepine derivatives
WO2024033457A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
US20260035364A1 (en) 2022-08-11 2026-02-05 Hoffmann-La Roche Inc. Bicyclic tetrahydrothiazepine derivatives
CN119677733A (zh) 2022-08-11 2025-03-21 豪夫迈·罗氏有限公司 双环四氢硫氮杂䓬衍生物
WO2024137865A1 (en) 2022-12-22 2024-06-27 Gossamer Bio Services, Inc. Compounds useful as t cell activators
CN121666382A (zh) 2023-05-10 2026-03-13 缆图药品公司 GSK3α抑制剂和其使用方法
EP4724149A1 (en) 2023-06-07 2026-04-15 Bristol-Myers Squibb Company Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
KR20260028777A (ko) 2023-06-23 2026-03-04 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 치환된 옥소이소인돌리닐 피페리딘-2,6-디온 화합물
WO2025030002A2 (en) 2023-08-02 2025-02-06 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
EP4784572A1 (en) 2023-09-02 2026-08-05 Bristol-Myers Squibb Company Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds
KR20260109851A (ko) 2023-10-31 2026-07-13 브리스톨-마이어스 스큅 컴퍼니 유비퀴틴 특이적 프로세싱 프로테아제 1 (usp1) 화합물
IL327996A (en) 2023-10-31 2026-06-01 Bristol Myers Squibb Co Ubiquitin specific processing protease 1 (usp1) compounds
CN122422311A (zh) 2023-10-31 2026-07-17 百时美施贵宝公司 泛素特异性加工蛋白酶1 (usp1)化合物
CN122180680A (zh) 2023-10-31 2026-06-09 百时美施贵宝公司 泛素特异性加工蛋白酶1(usp1)化合物
WO2025096487A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096494A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096490A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025226767A1 (en) 2024-04-24 2025-10-30 Bristol-Myers Squibb Company Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer
WO2026035787A1 (en) 2024-08-07 2026-02-12 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) macrocyles
CN118908989B (zh) * 2024-10-10 2024-12-17 江苏长泰药业股份有限公司 一种用于预防肺结节恶性转化的丙酮酸盐衍生物纳米雾化剂及其制备方法
WO2026080794A1 (en) 2024-10-11 2026-04-16 Bristol-Myers Squibb Company Chemical compounds useful for degrading proteins
WO2026090348A1 (en) 2024-10-24 2026-04-30 Mirati Therapeutics, Inc. The use of son of sevenless (sos) inhibitor compounds such as 7-substituted benzofurans to treat cancer
WO2026112386A1 (en) 2024-11-22 2026-05-28 Bristol-Myers Squibb Company Substituted oxoisoindolinyl piperidine-2,6-dione compounds and methods of degrading proteins

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3236855A (en) 1964-01-17 1966-02-22 Merck & Co Inc Certain n-phenyl(thiazole-hydroxamidine) compounds and their preparation
US3354174A (en) 1964-02-19 1967-11-21 Sterling Drug Inc 1-and 2-benzimidazolyl-lower-alkylamidoximes, amidines-, and guanidines
DE1453353A1 (de) 1964-02-20 1970-01-15 Nottmeyer Maschf Heinrich Maschine zum Einpressen von Duebeln in eine vorgebohrte Platte oder dergleichen Werkstueck
US3286855A (en) 1965-06-01 1966-11-22 Standard Trailer Company Crane extension and resulting crane assembly
US3553228A (en) * 1967-09-26 1971-01-05 Colgate Palmolive Co 3-substituted-4h(1)benzopyrano(3,4-d) isoxazoles
DE2040628A1 (de) 1970-08-17 1972-02-24 Fahlberg List Veb Neue herbizide Mittel
US3948928A (en) * 1972-03-17 1976-04-06 Dainippon Pharmaceutical Co., Ltd. 3-Substituted-1,2-benzisoxazoles and pharmaceutically acceptable acid addition salts thereof
JPS5621033B2 (me) 1973-09-05 1981-05-16
FR2323683A1 (fr) 1975-09-11 1977-04-08 Philagro Sa Nouveaux derives d'amidoximes, leur preparation et les compositions qui les contiennent
GB1501529A (en) * 1975-09-11 1978-02-15 Philagro Sa Derivatives of amidoximes
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4323681A (en) * 1980-09-29 1982-04-06 American Home Products Corporation 4-Amino-2-substituted-5-pyrimidinecarboxamidoximes and carbothioamides
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
JPS58208275A (ja) 1982-05-20 1983-12-03 Lion Corp ５−アミノ−ピラゾ−ル誘導体及び該化合物を含有する抗腫瘍剤
ATE25250T1 (de) * 1983-07-22 1987-02-15 Bayer Ag Substituierte furazane.
US4507485A (en) 1984-01-23 1985-03-26 Bristol-Myers Company 3,4-Disubstituted-1,2,5-oxadiazoles having histamine H2 -receptor antagonist activity
JPS60193968A (ja) * 1984-03-13 1985-10-02 Toyo Jozo Co Ltd シクロペンテン環を有するイミダゾ−ルアミドオキシムおよびその製造法
JPS6259283A (ja) 1985-09-10 1987-03-14 Kaken Pharmaceut Co Ltd セフアロスポリン化合物
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
JP2696342B2 (ja) * 1988-06-27 1998-01-14 日本曹達株式会社 アミジン誘導体、その製造方法及び殺ダニ剤・農園芸用殺菌剤
ES2051986T3 (es) 1988-07-05 1994-07-01 Akzo Nv Compuestos con actividad broncodilatadora.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JPH0420710A (ja) 1990-05-12 1992-01-24 Hitachi Home Tec Ltd ポットバーナの運転制御装置
JPH04297449A (ja) 1991-03-27 1992-10-21 Hokko Chem Ind Co Ltd Ｎ−ヒドロキシベンジルグアニジン誘導体および農園芸用殺菌剤
JPH05186458A (ja) 1991-04-26 1993-07-27 Japan Tobacco Inc 新規なベンゾピラン誘導体
FR2677019B1 (fr) * 1991-05-27 1994-11-25 Pf Medicament Nouvelles piperidines disubstituees-1,4, leur preparation et leur application en therapeutique.
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
JP2709677B2 (ja) * 1992-06-19 1998-02-04 株式会社大塚製薬工場 ホスホン酸ジエステル誘導体
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
FR2720396B1 (fr) * 1994-05-27 1996-06-28 Adir Nouveaux N-pyridyl carboxamides et dérivés leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5731315A (en) 1995-06-07 1998-03-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted sulfonic acid n- (aminoiminomethyl)phenylalkyl!-azaheterocyclamide compounds
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
EE9800116A (et) 1995-10-17 1998-10-15 Astra Pharmaceuticals Limited Farmatseutiliselt aktiivsed kinasoliini ühendid
WO1997030047A1 (en) * 1996-02-17 1997-08-21 Agrevo Uk Limited Fungicidal 1,2,4-oxadiazoles and analogues
US5955495A (en) 1996-05-03 1999-09-21 Hoffmann-La Roche Inc. Method of treating diseases of the CNS
JPH11171702A (ja) 1997-09-24 1999-06-29 Takeda Chem Ind Ltd 害虫防除方法
US6395876B1 (en) * 1997-12-05 2002-05-28 Medical College Of Georgia Research Institute, Inc. High-affinity tryptophan transporter
CN1188411C (zh) 1997-12-10 2005-02-09 大日本油墨化学工业株式会社 肟衍生物及含有它们的农药
DE69902387T2 (de) 1998-06-02 2003-02-13 Takeda Chemical Industries, Ltd. Oxadiazolinderivate und ihre verwendung als insektizide
ES2342240T3 (es) 1998-08-11 2010-07-02 Novartis Ag Derivados de isoquinolina con actividad que inhibe la angiogenia.
FR2784678B1 (fr) 1998-09-23 2002-11-29 Sod Conseils Rech Applic Nouveaux derives de n-(iminomethyl)amines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
WO2000052001A1 (en) 1999-03-03 2000-09-08 Samjin Pharmaceutical Co., Ltd. Piperazine derivatives and process for the preparation thereof
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
US7144902B1 (en) 1999-04-09 2006-12-05 Abbott Gmbh & Co. Kg Prodrugs of thrombin inhibitors
JP3893878B2 (ja) 1999-05-24 2007-03-14 三菱ウェルファーマ株式会社 フェノキシプロピルアミン化合物
JP2001158785A (ja) 1999-11-30 2001-06-12 Takeda Chem Ind Ltd 農薬組成物
JP2001158786A (ja) 1999-11-30 2001-06-12 Takeda Chem Ind Ltd 哺乳動物の外部寄生虫防除剤
CA2397575A1 (en) 2000-01-13 2001-07-19 Tularik Inc. Antibacterial agents
JP2001233861A (ja) 2000-02-22 2001-08-28 Ube Ind Ltd ピラゾールオキシム化合物、その製法及び用途
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
EP1294358B1 (en) 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process
GB0108102D0 (en) 2001-03-30 2001-05-23 Pfizer Ltd Compounds
BR0211030A (pt) 2001-06-18 2004-06-22 Applied Research Systems Derivado de pirrolidina oxadiazole, uso de um derivado de pirrolidina oxadiazole, composição farmacêutica contendo pelo menos um derivado de pirrolidina oxadiazole, método para preparação de um composto de pirrolidina oxadiazole
CN100391958C (zh) 2001-09-19 2008-06-04 安万特医药股份有限公司 化合物
EP1438059A4 (en) * 2001-10-26 2008-01-23 Angiolab Inc COMPOSITION CONTAINING EXTRACT OF BROWN FROM INDIA PREPARED FOR ANTI-ANGIOGENIC ACTIVITY AND INHIBITOR OF MATRIX METALLOPROTEINASE
PT1441737E (pt) 2001-10-30 2006-12-29 Dana Farber Cancer Inst Inc Derivados de estrutura como inibidores da actividade do receptor de tirosina cinase flt3
NZ534069A (en) 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
ES2281633T3 (es) 2002-02-19 2007-10-01 Pfizer Italia S.R.L. Derivados triciclicos de pirazol, procedimiento para su preparacion y su uso como agentes antitumorales.
GB0208224D0 (en) 2002-04-10 2002-05-22 Celltech R&D Ltd Chemical compounds
EP1501918A4 (en) 2002-04-12 2006-03-29 Med College Georgia Res Inst ANTIGEN PRESENTING CELL POPULATIONS AND THEIR USE AS REAGENTS TO INCREASE OR REDUCE IMMUNO TOLERANCE
UA80131C2 (en) 2002-05-28 2007-08-27 Dimensional Pharm Inc Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
JP4020710B2 (ja) 2002-06-25 2007-12-12 株式会社ミツバ ドアミラーセットプレート
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
US7157462B2 (en) 2002-09-24 2007-01-02 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7015321B2 (en) 2002-10-12 2006-03-21 The Scripps Research Institute Synthesis of non-symmetrical sulfamides using burgess-type reagents
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
WO2004072266A2 (en) 2003-02-13 2004-08-26 Kalobios Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
WO2004094409A1 (en) * 2003-03-27 2004-11-04 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use
US7598287B2 (en) 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
DK1639014T3 (da) 2003-06-13 2011-01-17 Biogen Idec Inc Aglycosyl-anti-CD154 (CD40-ligand)-antistoffer og anvendelser deraf
ATE536353T1 (de) 2003-08-20 2011-12-15 Vertex Pharma 2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazol- verbindungen als protein kinase inhibitoren
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
DE10348022A1 (de) * 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
DE10348023A1 (de) * 2003-10-15 2005-05-19 Imtm Gmbh Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
MXPA06014247A (es) 2004-06-10 2007-03-12 Irm Llc Compuestos y composiciones como inhibidores de la proteina quinasa.
CA2579207C (en) 2004-09-08 2011-10-18 Mitsubishi Pharma Corporation Morpholine compound
RU2007123675A (ru) 2004-11-24 2008-12-27 Новартис АГ (CH) Комбинации ингибиторов jak
EP1838706A1 (en) 2004-12-24 2007-10-03 Prosidion Limited G-protein coupled receptor agonists
US7429667B2 (en) * 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
DK1879573T3 (da) 2005-05-10 2013-02-25 Incyte Corp Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf
WO2006133417A1 (en) 2005-06-07 2006-12-14 Valeant Pharmaceuticals International Phenylamino isothiazole carboxamidines as mek inhibitors
AU2006265601A1 (en) 2005-06-30 2007-01-11 Anthrogenesis Corporation Repair of tympanic membrane using placenta derived collagen biofabric
DE102005060466A1 (de) * 2005-12-17 2007-06-28 Bayer Cropscience Ag Carboxamide
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
US20070203140A1 (en) * 2006-02-09 2007-08-30 Combs Andrew P N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
JP4297449B2 (ja) 2006-05-12 2009-07-15 株式会社サクラクレパス 墨汁
US20080146624A1 (en) * 2006-09-19 2008-06-19 Incyte Corporation Amidines as modulators of indoleamine 2,3-dioxygenase
WO2008036643A2 (en) 2006-09-19 2008-03-27 Incyte Corporation Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
CA2663057C (en) 2006-09-19 2015-12-08 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US20080182882A1 (en) * 2006-11-08 2008-07-31 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
EP2121621B1 (en) 2006-12-08 2014-05-07 Exelixis Patent Company LLC Lxr and fxr modulators
CL2008000066A1 (es) * 2007-01-12 2008-08-01 Smithkline Beecham Corp Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem
AU2008343932B2 (en) 2007-12-19 2013-08-15 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
CA3012229C (en) 2008-07-08 2020-11-10 Incyte Holdings Corporation 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
KR102186969B1 (ko) 2010-10-25 2020-12-04 쥐원 쎄라퓨틱스, 인크. Cdk 억제제
KR101606250B1 (ko) 2011-03-23 2016-03-24 암젠 인크 Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제
CA2889182A1 (en) 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
JP6357475B2 (ja) 2013-07-12 2018-07-11 日本ケミファ株式会社 Ｐ２ｘ４受容体拮抗剤
EP3744715A1 (en) 2013-11-08 2020-12-02 Incyte Holdings Corporation Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor
PH12020550847A1 (en) 2014-02-04 2022-05-11 Incyte Corp Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
PE20231958A1 (es) 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
UA125747C2 (uk) 2015-09-01 2022-06-01 Фьост Вейв Байо, Інк. Способи та композиції для лікування станів, пов'язаних із аномальною запальною відповіддю
CN108472245A (zh) 2015-11-04 2018-08-31 因赛特公司 用于吲哚胺2,3-双加氧酶抑制及其适应症的药物组合物和方法
WO2021022172A1 (en) 2019-08-01 2021-02-04 Incyte Corporation A dosing regimen for an ido inhibitor
JP2023523319A (ja) 2020-04-27 2023-06-02 アルマタ・ファーマシューティカルズ・インコーポレーテッド シュードモナス感染症を処置するためのバクテリオファージ組成物

Also Published As

Publication number Publication date
AR054271A1 (es) 2007-06-13
EP1879573A1 (en) 2008-01-23
NO342140B1 (no) 2018-03-26
PT1879573E (pt) 2013-03-25
CN103130735B (zh) 2016-08-03
GEP20217221B (en) 2021-02-10
BRPI0608604B1 (pt) 2020-11-17
CA2606783A1 (en) 2006-11-16
BRPI0608604B8 (pt) 2021-05-25
SG195607A1 (en) 2013-12-30
MY153424A (en) 2015-02-13
EA026785B1 (ru) 2017-05-31
BRPI0608604A2 (pt) 2010-01-26
CN101212967A (zh) 2008-07-02
US8372870B2 (en) 2013-02-12
RS54876B1 (sr) 2016-10-31
AU2006244068A1 (en) 2006-11-16
CN103130735A (zh) 2013-06-05
JP5615308B2 (ja) 2014-10-29
KR20080005954A (ko) 2008-01-15
SI2559690T1 (sl) 2016-06-30
US20060258719A1 (en) 2006-11-16
EP1879573B1 (en) 2012-12-19
DK1879573T3 (da) 2013-02-25
JP4990270B2 (ja) 2012-08-01
US20110311479A1 (en) 2011-12-22
ZA200709698B (en) 2008-11-26
NO20075693L (no) 2008-02-07
BR122020016659B8 (pt) 2021-07-27
AU2006244068B2 (en) 2012-06-14
PT2559690T (pt) 2016-07-07
IL232313A (en) 2016-05-31
IL232313A0 (en) 2014-06-30
HK1182381A1 (en) 2013-11-29
JP2008540548A (ja) 2008-11-20
US8034953B2 (en) 2011-10-11
AU2006244068B9 (en) 2012-10-25
EP2559690A1 (en) 2013-02-20
SG10201809390QA (en) 2018-11-29
US20140377292A1 (en) 2014-12-25
CY1117681T1 (el) 2017-05-17
US10208002B2 (en) 2019-02-19
ES2401482T3 (es) 2013-04-22
KR101386494B1 (ko) 2014-04-24
IL186957A (en) 2014-04-30
UA99897C2 (en) 2012-10-25
HUE029214T2 (en) 2017-02-28
PL1879573T3 (pl) 2013-05-31
IL186957A0 (en) 2008-02-09
MX2007013977A (es) 2008-02-05
RS52711B (sr) 2013-08-30
EP3085697A1 (en) 2016-10-26
US20130123246A1 (en) 2013-05-16
KR101562549B1 (ko) 2015-10-23
US8846726B2 (en) 2014-09-30
EP1879573A4 (en) 2009-07-08
PL2559690T3 (pl) 2016-09-30
SG161310A1 (en) 2010-05-27
US11192868B2 (en) 2021-12-07
CR9485A (es) 2008-02-20
JP2012140450A (ja) 2012-07-26
HRP20160537T1 (hr) 2016-06-17
EP2559690B1 (en) 2016-03-30
KR20130109263A (ko) 2013-10-07
US20190210985A1 (en) 2019-07-11
EA200702455A1 (ru) 2008-04-28
TWI377060B (en) 2012-11-21
CY1113989T1 (el) 2016-07-27
NO20170633A1 (no) 2008-02-07
HK1117392A1 (en) 2009-01-16
ES2578404T3 (es) 2016-07-26
TW200719892A (en) 2007-06-01
DK2559690T3 (en) 2016-04-25
HRP20130220T1 (hr) 2013-04-30
SI1879573T1 (sl) 2013-04-30
BR122020016659B1 (pt) 2021-03-16
NZ562919A (en) 2011-04-29
WO2006122150A1 (en) 2006-11-16
CA2606783C (en) 2014-03-25
US20180030006A1 (en) 2018-02-01
NO340487B1 (no) 2017-05-02

Similar Documents

Publication Publication Date Title
HRP20160537T1 (hr) Modulatori indolamina 2,3-dioksigenaze i metode za upotrebu istih
JP2010504342A5 (me)
RU2461551C2 (ru) Азолкарбоксамидное соединение или его фармацевтически приемлемая соль
JP2009529557A5 (me)
RU2006101053A (ru) Производные бензамида или соль указанного производного
JP2015517981A5 (me)
JP2007519754A5 (me)
HRP20150442T1 (hr) Sredstva za izazivanje apoptoze za lijeäśenje raka i imunih i autoimunih bolesti
RU2017145650A (ru) Ингибиторы тирозинкиназы брутона
JP2010501587A5 (me)
RU2008119412A (ru) N-фенил-фенилацетамидные ненуклеозидные ингибиторы обратной транскриптазы
JP2005521639A5 (me)
FI3743406T3 (fi) Tmem16a-modulaattoreita
JP2021512143A5 (me)
HRP20161085T1 (hr) Sulfonamid derivati kao bcl-2 selektivni agensi za induciranje apoptoze namijenjeni liječenju raka i imunih bolesti
RU2007107189A (ru) Производные арилпиридина
ZA200502755B (en) 1,3-Diamino-2-hydroxypropane prodrug derivatives.
JP2009528354A5 (me)
JP2002532415A5 (ja) Ｍｅｋ阻害剤を含有する関節炎の治療用医薬組成物
RU2004126936A (ru) Производные хинолина в качестве антагонистов npv
RU2007119427A (ru) Соединения, являющиеся ингибиторами гликогенфосфорилазы, и фармацевтические композиции на их основе
RU2009118254A (ru) Фенилацетамиды в качестве ингибиторов протеинкиназ
JP2010506918A5 (me)
NZ603724A (en) Piperidine derivatives and their use for the treatment of metabolic disorders
RU2012121684A (ru) Производные оксазолина для лечения заболеваний цнс